<p>Amylyx Pharmaceuticals（纳斯达克代码：AMLX - 获取免费报告）于周四发布了季度财报。公司报告每股收益（EPS）为（$0.37），低于市场共识预期的（$0.34），差距为（$0.03），FiscalAI 报道。</p>
<ul>
<li>3 家小型生物科技公司，2024 年有潜在突破</li>
</ul>
<p>以下是 Amylyx Pharmaceuticals 电话会议的关键要点：</p>
<ul>
<li><strong>Avexitide LUCIDITY</strong> 在 3 月底随机分配并给最后一名参与者用药，仍按计划完成为期 16 周的试验，预计在 2026 年第三季度公布初步结果，同时 NDA 部分已在起草中，以支持 2027 年可能的批准和上市，如果结果积极。</li>
<li>公司启动了一项美国扩展接入计划，最多可容纳 250 名成年人，并计划在今夏启动疾病状态教育活动，并引用独立的基于索赔的市场估计，约有 <strong>160,000</strong> 名美国人患有 PBH，内分泌科医生在可用的批准疗法出现时表现出强烈的治疗意愿。</li>
<li>Amylyx 报告现金和可交易证券为 2.798 亿美元，并表示这笔资金将支持预计到 <strong>2028</strong> 年的现金流，涵盖包括 LUCIDITY 结果公布和潜在商业化活动在内的关键里程碑。</li>
<li>更广泛的管道进展包括针对长效 GLP-1 拮抗剂 <strong>AMX0318</strong> 的 IND 启用工作（目标为 2027 年 IND）、即将公布的 Wolfram 综合症 <strong>AMX0035</strong> 的第 96 周数据，以及预计在即将召开的科学会议上公布的 <strong>AMX0114</strong> ALS 试验第一组的生物标志物数据。</li>
<li>第一季度运营费用上升至 4380 万美元（同比增长 16%），主要由于对 avexitide 的研发支出增加，以及向 Gubra 支付的 400 万美元里程碑款项，此外，由于该付款和年度奖金，公司本季度现金使用略有增加。</li>
</ul>
<p>获取 <strong>Amylyx Pharmaceuticals</strong> 的提醒：</p>
<h2>Amylyx Pharmaceuticals 价格表现</h2>
<p>周四交易时段，AMLX 下跌 0.86 美元，达到 15.20 美元。共有 1,451,469 股股票交易，较其平均交易量 1,021,572 股有所增加。该公司的 50 日简单移动平均为 15.36 美元，200 日简单移动平均为 14.26 美元。公司市值为 16.9 亿美元，市盈率为-9.81，贝塔值为-0.11。Amylyx Pharmaceuticals 的 52 周低点为 4.20 美元，52 周高点为 18.60 美元。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>这些生物科技公司针对多种神经退行性疾病</li>
</ul>
<p>几位股票研究分析师最近对 AMLX 股票发布了报告。美国银行在 2 月 20 日的研究报告中将 Amylyx Pharmaceuticals 的目标价从 15.00 美元上调至 19.00 美元，并给予该股票 “买入” 评级。Wall Street Zen 在 3 月 7 日的研究报告中将 Amylyx Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。瑞穗证券在 4 月 28 日的研究报告中将 Amylyx Pharmaceuticals 的目标价从 19.00 美元上调至 21.00 美元，并给予该股票 “跑赢大盘” 评级。古根海姆在 3 月 19 日的研究报告中将 Amylyx Pharmaceuticals 的目标价从 25.00 美元上调至 30.00 美元，并给予该股票 “买入” 评级。最后，HC Wainwright 在 3 月 25 日的研究报告中重申了 “买入” 评级，并对 Amylyx Pharmaceuticals 的目标价设定为 34.00 美元。一位投资分析师给予该股票 “强烈买入” 评级，九位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 23.00 美元。</p>
<p><strong>查看我们对 Amylyx Pharmaceuticals 的最新分析</strong></p>
<h2>机构投资者对 Amylyx Pharmaceuticals 的看法</h2>
<ul>
<li>Amylyx Pharmaceuticals 在成功推出药物后实现盈利</li>
</ul>
<p>大型投资者最近增加或减少了对公司的持股。Meeder Asset Management Inc.在第四季度收购了价值 25,000 美元的 Amylyx Pharmaceuticals 新股份。加州教师退休系统在第二季度收购了价值 28,000 美元的 Amylyx Pharmaceuticals 新股份。Legal &amp; General Group Plc 在第二季度收购了价值 47,000 美元的 Amylyx Pharmaceuticals 新股份。法国巴黎银行金融市场在第二季度将其在 Amylyx Pharmaceuticals 的持股增加了 433.2%。法国巴黎银行金融市场目前拥有 7267 股该公司的股票，价值 47,000 美元，此前在上个季度又购买了 5904 股。最后，凯通国际资产管理有限公司在第四季度将其在 Amylyx Pharmaceuticals 的持股增加了 1,116.9%。凯通国际资产管理有限公司目前拥有 4454 股该公司的股票，价值 54,000 美元，此前在上个季度又购买了 4088 股。95.84% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Amylyx Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Amylyx Pharmaceuticals, Inc 是一家生物制药公司，致力于开发针对罕见和严重神经疾病的治疗方案。公司成立于 2013 年，总部位于马萨诸塞州剑桥，专注于利用新颖的方法针对与神经退行性疾病相关的细胞通路。Amylyx 的研究平台以小分子疗法为中心，旨在保护神经元并支持患有目前缺乏或没有疾病修饰治疗选项的患者的细胞健康。</p>
<p>公司的主要产品 AMX0035 在美国以 Relyvrio 的商标销售。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Amylyx Pharmaceuticals</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1MWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1MWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Amylyx Pharmaceuticals 吗？</h2>
<p>在考虑投资 Amylyx Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意之前购买的股票……而 Amylyx Pharmaceuticals 并不在名单上。</p>
<p>虽然 Amylyx Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AMLX

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

基因改革 ETF - ARK

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

<p>Amylyx Pharmaceuticals（纳斯达克代码：AMLX）报告的季度每股收益为（$0.37），低于预期$0.03。该公司拥有 2.798 亿美元的现金，足以支持运营到 2028 年。主要进展包括 LUCIDITY 试验和美国扩展接入计划。分析师设定了新的价格目标，普遍评级为 “适度买入”，目标价为$23.00。机构投资者持有 95.84% 的股份，显示出对该公司的强烈兴趣</p>

<p>Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03), FiscalAI reports.</p>
<div class="lb-trans"><p>Amylyx Pharmaceuticals（纳斯达克代码：AMLX - 获取免费报告）于周四发布了季度财报。公司报告每股收益（EPS）为（$0.37），低于市场共识预期的（$0.34），差距为（$0.03），FiscalAI 报道。</p>
</div><ul>
<li>3 small-cap biotechs with potential breakthroughs in 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家小型生物科技公司，2024 年有潜在突破</li>
</ul>
</div><p>Here are the key takeaways from Amylyx Pharmaceuticals' conference call:</p>
<div class="lb-trans"><p>以下是 Amylyx Pharmaceuticals 电话会议的关键要点：</p>
</div><ul>
<li><strong>Avexitide LUCIDITY</strong> randomized and dosed its last participant in late March and remains on track to complete the 16-week trial with a top-line readout expected in Q3 2026, while NDA sections are already being drafted to support a potential 2027 approval and launch if results are positive.</li>
<li>The company launched a U.S. expanded access program for up to 250 adults, is initiating a disease‑state education campaign this summer, and cites an independent claims-based market estimate of ~ <strong>160,000</strong> people in the U.S. with PBH, with endocrinologists showing high intent to treat if an approved therapy becomes available.</li>
<li>Amylyx reported $279.8 million in cash and marketable securities and says this capital funds an anticipated cash runway into <strong>2028</strong>, covering key milestones including the LUCIDITY readout and potential commercialization activities.</li>
<li>Broader pipeline progress includes IND‑enabling work for the long‑acting GLP‑1 antagonist <strong>AMX0318</strong> (targeting a 2027 IND), forthcoming week‑96 data for <strong>AMX0035</strong> in Wolfram syndrome, and biomarker data from cohort 1 of the <strong>AMX0114</strong> ALS trial expected at an upcoming scientific meeting.</li>
<li>Q1 operating expenses rose to $43.8 million (up 16% year‑over‑year) driven by higher R&amp;D spend on avexitide and a $4.0 million milestone payment to Gubra, and the company reported slightly higher cash usage this quarter due to that payment and annual bonuses.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Avexitide LUCIDITY</strong> 在 3 月底随机分配并给最后一名参与者用药，仍按计划完成为期 16 周的试验，预计在 2026 年第三季度公布初步结果，同时 NDA 部分已在起草中，以支持 2027 年可能的批准和上市，如果结果积极。</li>
<li>公司启动了一项美国扩展接入计划，最多可容纳 250 名成年人，并计划在今夏启动疾病状态教育活动，并引用独立的基于索赔的市场估计，约有 <strong>160,000</strong> 名美国人患有 PBH，内分泌科医生在可用的批准疗法出现时表现出强烈的治疗意愿。</li>
<li>Amylyx 报告现金和可交易证券为 2.798 亿美元，并表示这笔资金将支持预计到 <strong>2028</strong> 年的现金流，涵盖包括 LUCIDITY 结果公布和潜在商业化活动在内的关键里程碑。</li>
<li>更广泛的管道进展包括针对长效 GLP-1 拮抗剂 <strong>AMX0318</strong> 的 IND 启用工作（目标为 2027 年 IND）、即将公布的 Wolfram 综合症 <strong>AMX0035</strong> 的第 96 周数据，以及预计在即将召开的科学会议上公布的 <strong>AMX0114</strong> ALS 试验第一组的生物标志物数据。</li>
<li>第一季度运营费用上升至 4380 万美元（同比增长 16%），主要由于对 avexitide 的研发支出增加，以及向 Gubra 支付的 400 万美元里程碑款项，此外，由于该付款和年度奖金，公司本季度现金使用略有增加。</li>
</ul>
</div><p>Get <strong>Amylyx Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Amylyx Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Amylyx Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Amylyx Pharmaceuticals 价格表现</h2>
</div><p>AMLX traded down $0.86 during trading hours on Thursday, reaching $15.20. 1,451,469 shares of the stock traded hands, compared to its average volume of 1,021,572. The firm's fifty day simple moving average is $15.36 and its two-hundred day simple moving average is $14.26. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -9.81 and a beta of -0.11. Amylyx Pharmaceuticals has a fifty-two week low of $4.20 and a fifty-two week high of $18.60.</p>
<div class="lb-trans"><p>周四交易时段，AMLX 下跌 0.86 美元，达到 15.20 美元。共有 1,451,469 股股票交易，较其平均交易量 1,021,572 股有所增加。该公司的 50 日简单移动平均为 15.36 美元，200 日简单移动平均为 14.26 美元。公司市值为 16.9 亿美元，市盈率为-9.81，贝塔值为-0.11。Amylyx Pharmaceuticals 的 52 周低点为 4.20 美元，52 周高点为 18.60 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>These biotechs targeting multiple neurodegenerative diseases</li>
</ul>
<div class="lb-trans"><ul>
<li>这些生物科技公司针对多种神经退行性疾病</li>
</ul>
</div><p>Several equities research analysts have recently issued reports on AMLX shares. Bank of America increased their price objective on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, February 20th. Wall Street Zen raised shares of Amylyx Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, March 7th. Mizuho increased their price objective on shares of Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, April 28th. Guggenheim increased their price objective on shares of Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, March 19th. Finally, HC Wainwright reissued a &#34;buy&#34; rating and issued a $34.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $23.00.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 AMLX 股票发布了报告。美国银行在 2 月 20 日的研究报告中将 Amylyx Pharmaceuticals 的目标价从 15.00 美元上调至 19.00 美元，并给予该股票 “买入” 评级。Wall Street Zen 在 3 月 7 日的研究报告中将 Amylyx Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。瑞穗证券在 4 月 28 日的研究报告中将 Amylyx Pharmaceuticals 的目标价从 19.00 美元上调至 21.00 美元，并给予该股票 “跑赢大盘” 评级。古根海姆在 3 月 19 日的研究报告中将 Amylyx Pharmaceuticals 的目标价从 25.00 美元上调至 30.00 美元，并给予该股票 “买入” 评级。最后，HC Wainwright 在 3 月 25 日的研究报告中重申了 “买入” 评级，并对 Amylyx Pharmaceuticals 的目标价设定为 34.00 美元。一位投资分析师给予该股票 “强烈买入” 评级，九位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 23.00 美元。</p>
</div><p><strong>View Our Latest Analysis on Amylyx Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Amylyx Pharmaceuticals 的最新分析</strong></p>
</div><h2>Institutional Investors Weigh In On Amylyx Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Amylyx Pharmaceuticals 的看法</h2>
</div><ul>
<li>Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch</li>
</ul>
<div class="lb-trans"><ul>
<li>Amylyx Pharmaceuticals 在成功推出药物后实现盈利</li>
</ul>
</div><p>Large investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. acquired a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at $25,000. California State Teachers Retirement System acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at $28,000. Legal &amp; General Group Plc acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at $47,000. BNP Paribas Financial Markets grew its holdings in Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company's stock valued at $47,000 after purchasing an additional 5,904 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Amylyx Pharmaceuticals by 1,116.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,454 shares of the company's stock valued at $54,000 after purchasing an additional 4,088 shares in the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对公司的持股。Meeder Asset Management Inc.在第四季度收购了价值 25,000 美元的 Amylyx Pharmaceuticals 新股份。加州教师退休系统在第二季度收购了价值 28,000 美元的 Amylyx Pharmaceuticals 新股份。Legal &amp; General Group Plc 在第二季度收购了价值 47,000 美元的 Amylyx Pharmaceuticals 新股份。法国巴黎银行金融市场在第二季度将其在 Amylyx Pharmaceuticals 的持股增加了 433.2%。法国巴黎银行金融市场目前拥有 7267 股该公司的股票，价值 47,000 美元，此前在上个季度又购买了 5904 股。最后，凯通国际资产管理有限公司在第四季度将其在 Amylyx Pharmaceuticals 的持股增加了 1,116.9%。凯通国际资产管理有限公司目前拥有 4454 股该公司的股票，价值 54,000 美元，此前在上个季度又购买了 4088 股。95.84% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Amylyx Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Amylyx Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.</p>
<div class="lb-trans"><p>Amylyx Pharmaceuticals, Inc 是一家生物制药公司，致力于开发针对罕见和严重神经疾病的治疗方案。公司成立于 2013 年，总部位于马萨诸塞州剑桥，专注于利用新颖的方法针对与神经退行性疾病相关的细胞通路。Amylyx 的研究平台以小分子疗法为中心，旨在保护神经元并支持患有目前缺乏或没有疾病修饰治疗选项的患者的细胞健康。</p>
</div><p>The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.</p>
<div class="lb-trans"><p>公司的主要产品 AMX0035 在美国以 Relyvrio 的商标销售。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Amylyx Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Amylyx Pharmaceuticals</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1MWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=AMLX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Amylyx Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Amylyx Pharmaceuticals 吗？</h2>
</div><p>Before you consider Amylyx Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Amylyx Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意之前购买的股票……而 Amylyx Pharmaceuticals 并不在名单上。</p>
</div><p>While Amylyx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Amylyx Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Amylyx Pharmaceuticals (NASDAQ:AMLX) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Market Beat

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals（纳斯达克股票代码：AMLX）公布季度财报，每股收益比预期低 0.03 美元